Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study.
Marc HilmiStéphane EderhyXavier WaintraubChristian Funck-BrentanoAriel CohenAurore VozyBénédicte Lebrun-VignesJavid MoslehiLee S NguyenJoe-Elie SalemPublished in: Pharmaceuticals (Basel, Switzerland) (2020)
Treatment with gemcitabine is associated with potentially lethal CV-ADRs, including MI, pericardial diseases, SVA and HF. These events should be considered in patient care and clinical trial design.